Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 11/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL29770051 | 1.00 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655666 | 0.97 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655665 | 0.86 | NPC1 (0.55) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL146559 | 0.82 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655809 | 0.82 | CYP3A4 (0.50) | NPC1RAB9ACYP11B1CYP11B2CYP3A4 | |
| Trifluoromethanesulfonic Acid SCHEMBL29770052 | 0.82 | CYP3A4 (0.50) | NPC1RAB9ACYP11B1CYP11B2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28148550 | 0.81 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655587 | 0.80 | CYP1A2 (0.41) | RAB9ACYP3A4TP53 | |
| SCHEMBL152870 | 0.79 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2CYP11B1CYP11B2 | |
| Trifluoromethanesulfonic Acid SCHEMBL14655808 | 0.79 | CYP3A4 (0.50) | NPC1RAB9ACYP11B1CYP11B2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2024-04-25 | — | — | US | disclosed |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20220302396-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2022-09-22 | — | — | US | disclosed |
| US-11380854-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2022-07-05 | — | — | US | disclosed |
| US-20190245153-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2019-08-08 | — | — | US | disclosed |
| US-10312458-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| US-20160099425-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION | 2016-04-07 | — | — | US | disclosed |
| US-9184397-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2551933-B1 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20140159028-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-8709615-B2 | Heteroleptic iridium complexes as dopants | UNIVERSAL DISPLAY CORPORATION (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130026452-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | UNIVERSAL DISPLAY CORPORATION (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2551933-A1 | Heteroleptic iridium complexes as dopants | Universal Display Corporation (US) | 2013-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160099425-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20140159028-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20190245153-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-10312458-B2 | Organic electroluminescent materials and devices | JUND, OCIAD1, OCIAD2 | NPC1 1062/4885RAB9A 2128/4885SMN1; SMN2 3567/4885 |
| US-20240138251-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20130026452-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-11380854-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-11910700-B2 | Heteroleptic iridium complexes as dopants | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
| US-20220302396-A1 | HETEROLEPTIC IRIDIUM COMPLEXES AS DOPANTS | JUND, DRD2, DRD1 | NPC1 946/4885RAB9A 1245/4885SMN1; SMN2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.